Neoadjuvant Therapy in Esophageal Cancer

Shirley Lewis, Jelena Lukovic

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Locally advanced esophageal cancer has a dismal prognosis. Surgery remains the cornerstone treatment with 5-year survival rates of approximately 12-39%. Rates of local failure and distant metastases are high following surgical resection of locally advanced tumors. Neoadjuvant therapy (either radiation therapy, chemotherapy, or a combination) prior to surgery carries the advantage of tackling micrometastases and improving complete resection rates. Neoadjuvant concurrent chemotherapy and radiotherapy are a favored approach with evidence for improved pathologic complete response (pCR) rates and improved survival compared with surgery alone. Randomized trials of the optimal neoadjuvant approach are ongoing.

Original languageEnglish
Pages (from-to)447-456
Number of pages10
JournalThoracic Surgery Clinics
Issue number4
Publication statusPublished - 01-11-2022

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Neoadjuvant Therapy in Esophageal Cancer'. Together they form a unique fingerprint.

Cite this